These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17580169)

  • 1. Living donor liver transplantation from hepatitis B core antibody positive donors.
    Celebi Kobak A; Karasu Z; Kilic M; Ozacar T; Tekin F; Gunsar F; Ersoz G; Yuzer Y; Tokat Y
    Transplant Proc; 2007 Jun; 39(5):1488-90. PubMed ID: 17580169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.
    Xi ZF; Xia Q; Zhang JJ; Chen XS; Han LZ; Zhu JJ; Wang SY; Qiu DK
    J Dig Dis; 2013 Aug; 14(8):439-45. PubMed ID: 23638710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine.
    Nery JR; Nery-Avila C; Reddy KR; Cirocco R; Weppler D; Levi DM; Nishida S; Madariaga J; Kato T; Ruiz P; Schiff E; Tzakis AG
    Transplantation; 2003 Apr; 75(8):1179-86. PubMed ID: 12717200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
    Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
    Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation.
    Holt D; Thomas R; Van Thiel D; Brems JJ
    Arch Surg; 2002 May; 137(5):572-5; discussion 575-6. PubMed ID: 11982471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors.
    Dodson SF; Bonham CA; Geller DA; Cacciarelli TV; Rakela J; Fung JJ
    Transplantation; 1999 Oct; 68(7):1058-61. PubMed ID: 10532552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors.
    Chen YS; Wang CC; de Villa VH; Wang SH; Cheng YF; Huang TL; Jawan B; Chiu KW; Chen CL
    Clin Transplant; 2002 Dec; 16(6):405-9. PubMed ID: 12437618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors?
    Loss GE; Mason AL; Nair S; Blazek J; Farr G; Guo L; Cohen AJ; Eason JD
    Liver Transpl; 2003 Dec; 9(12):1258-64. PubMed ID: 14625825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.
    Suehiro T; Shimada M; Kishikawa K; Shimura T; Soejima Y; Yoshizumi T; Hashimoto K; Mochida Y; Maehara Y; Kuwano H
    Liver Int; 2005 Dec; 25(6):1169-74. PubMed ID: 16343068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
    Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
    J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
    Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HBc-positive/HBsAg-negative liver donors pose a higher risk of occult HBV infection but do not cause severe histological damage in liver grafts.
    Niu Y; Chen X; Feng L; You H; Ren X; Liu H; Zheng J; Shen Z; Jia J
    Clin Res Hepatol Gastroenterol; 2014 Sep; 38(4):475-80. PubMed ID: 24835492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
    Prieto M; Gómez MD; Berenguer M; Córdoba J; Rayón JM; Pastor M; García-Herola A; Nicolás D; Carrasco D; Orbis JF; Mir J; Berenguer J
    Liver Transpl; 2001 Jan; 7(1):51-8. PubMed ID: 11150423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and treatment strategies for de novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.
    Dong C; Gao W; Ma N; Sun C; Zheng WP; Wang K; Shen ZY
    Pediatr Transplant; 2017 Mar; 21(2):. PubMed ID: 27933716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver grafts from anti-hepatitis B core positive donors: a systematic review.
    Cholongitas E; Papatheodoridis GV; Burroughs AK
    J Hepatol; 2010 Feb; 52(2):272-9. PubMed ID: 20034693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
    Vizzini G; Gruttadauria S; Volpes R; D'Antoni A; Pietrosi G; Filì D; Petridis I; Pagano D; Tuzzolino F; Santonocito MM; Gridelli B
    Clin Transplant; 2011; 25(1):E77-81. PubMed ID: 21039887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors.
    Roque-Afonso AM; Feray C; Samuel D; Simoneau D; Roche B; Emile JF; Gigou M; Shouval D; Dussaix E
    Gut; 2002 Jan; 50(1):95-9. PubMed ID: 11772974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.